Again, using animal models (EMT6, a Lewis Lung Carcinoma model, LCC, and melanoma), Pilch et al. reported that while agonistic CD200R antibodies (two were tested) reached tumors, they had no significant impact on tumor growth and only a minor effect on the infiltration of immune myeloid cells [93]. Here, CD200R1 is linked to neoplasm.